Literature DB >> 8740405

The need for standardized pathologic staging of pancreaticoduodenectomy specimens.

C A Staley1, K R Cleary, J L Abbruzzese, J E Lee, F C Ames, C J Fenoglio, D B Evans.   

Abstract

A standardized method for pathologic evaluation and staging of pancreaticoduodenectomy (PD) specimens is critical for accurate reporting of the number and location of lymph nodes and margins of resection. We examined the impact of standardized pathologic evaluation (SPE) of PD specimens on the identification of regional lymph nodes and describe our detailed system for the pathologic analysis of the PD specimen. Forty consecutive patients underwent PD for histologically confirmed adenocarcinoma of the pancreatic head between April 1990 and August 1993. Fifteen consecutive specimens were examined before the introduction of the SPE, and 25 consecutive specimens underwent SPE. Resection margins were evaluated by frozen-section analysis, and then the specimen was divided into six regions on an anatomic dissection board for lymph node identification. The 25 specimens examined according to the SPE had a significantly increased number of lymph nodes identified (P = 0.0001) compared with the 15 specimens examined without the SPE. Twelve of the 25 specimens contained positive lymph nodes, 6 of which were confined to the pancreaticoduodenal region. No positive nodes were found in the periaortic region. There were no differences in pathologic variables between patients found to have negative and those with positive regional lymph nodes. SPE of PD specimens provides a method for improved lymph node identification, ensures accurate prospective evaluation of margins of resection, and provides a complete analysis of potentially important pathologic variables. We offer this system as a standardized model for groups engaged in protocol-based clinical research examining innovative multimodality treatment strategies for patients with resectable pancreatic cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8740405     DOI: 10.1097/00006676-199605000-00009

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  35 in total

Review 1.  Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas.

Authors:  D B Evans
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

3.  Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.

Authors:  Ryan M Thomas; Mark J Truty; Graciela M Nogueras-Gonzalez; Jason B Fleming; Jean-Nicolas Vauthey; Peter W T Pisters; Jeffrey E Lee; David C Rice; Wayne L Hofstetter; Robert A Wolff; Gauri R Varadhachary; Huamin Wang; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

4.  A novel approach to the intraoperative assessment of the uncinate margin of the pancreaticoduodenectomy specimen.

Authors:  Mahmoud A Khalifa; Vlad Maksymov; Corwyn H Rowsell; Sherif Hanna
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 5.  Retroperitoneal margin of the pancreaticoduodenectomy specimen: anatomic mapping for the surgical pathologist.

Authors:  Mahmoud A Khalifa; Vlad Maksymov; Corwyn Rowsell
Journal:  Virchows Arch       Date:  2008-12-06       Impact factor: 4.064

6.  Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.

Authors:  Tsutomu Fujii; Sohei Satoi; Suguru Yamada; Kenta Murotani; Hiroaki Yanagimoto; Hideki Takami; Tomohisa Yamamoto; Mitsuro Kanda; So Yamaki; Satoshi Hirooka; Masanori Kon; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2016-05-11       Impact factor: 7.527

7.  Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors.

Authors:  N Volkan Adsay; Olca Basturk; Burcu Saka; Pelin Bagci; Denizhan Ozdemir; Serdar Balci; Juan M Sarmiento; David A Kooby; Charles Staley; Shishir K Maithel; Rhonda Everett; Jeanette D Cheng; Duangpeng Thirabanjasak; Donald W Weaver
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

8.  CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.

Authors:  Mathilde Wagner; Celia Antunes; Daniel Pietrasz; Christophe Cassinotto; Magaly Zappa; Antonio Sa Cunha; Oliver Lucidarme; Jean-Baptiste Bachet
Journal:  Eur Radiol       Date:  2016-11-28       Impact factor: 5.315

9.  The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment.

Authors:  N Volkan Adsay; Olca Basturk; Deniz Altinel; Fayyaz Khanani; Ipek Coban; Donald W Weaver; David A Kooby; Juan M Sarmiento; Charles Staley
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

10.  Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.

Authors:  Jan Franko; Alyssa M Krasinskas; Marina N Nikiforova; Narcis O Zarnescu; Kenneth K W Lee; Steven J Hughes; David L Bartlett; Herbert J Zeh; A James Moser
Journal:  J Gastrointest Surg       Date:  2008-08-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.